Makers of EnLyte Proud To Support Annual Meeting of the American Association of Nurse Practitioners

SUNSET, La., June 8, 2015 (GLOBE NEWSWIRE) -- The national meeting of the American Association of Nurse Practitioners begins June 9th in New Orleans, bringing together over 5,000 nurse practitioners from numerous specialties. Sessions will include first-line treatments of depression in the primary care setting as well as mental health pharmacology updates for women's health and adolescents, making EnLyte the perfect fit for these important discussions. EnLyte has gained tremendous support in the Psychiatric Nurse Practitioner community, and JayMac Pharmaceuticals looks forward to expanding on this support at the meeting.

EnLyte is an advanced generation folate therapy by prescription containing Delta Folate: L-Methylfolate Magnesium, Folinic Acid, and Folacin, as well as the brain ready metabolites of key cofactors b1, b2, b3, b6, b12, betaine, plus zinc, magnesium, vitamin c, as well as PS gold omega 3s. EnLyte contains the necessary ingredients to address the remethylation and transsulfuration cycles. It is an FDA-regulated, prescription product for use in conditions related to folate deficiency and/or high homocysteine, including as monotherapy in mild depression or add-on therapy to an SSRI/SNRI in moderate or severe depression. It is increasingly being prescribed as a homocysteine-lowering agent to address the needs of patients with cardiovascular disease, cardiometabolic syndrome, and at risk for neurological diseases such as Alzheimer's, dementia, or Parkinson's.

EnLyte has been clinically proven to reduce the harmful amino acid, homocysteine, which is implicated in many chronic health conditions: stroke, dementia, Parkinson's, cardiovascular disease, depression, neural tube defects, repeated miscarriage, and autism. In an 8 week randomized, placebo-controlled study of 330 MTHFR polymorphic patients, EnLyte lowered homocysteine by week 2, for an overall reduction score of 33%. Placebo treated patients experienced a continued increase of homocysteine levels over the course of the study.

EnLyte is easily dosed as one gel cap per day with no side effect nor drug-drug interaction concerns. EnLyte is paid by many private health insurance plans and state Medicaid plans at a reasonable copay and is $58 per month through cash-pay mail order. For more information, contact EnLyte Customer Care, 985-788-7755, or visit www.EnLyteRx.Com.